Clinical trial
A Study of MLN8054 in Patients With Advanced Solid Tumors
NCT00249301 · Millennium Pharmaceuticals, Inc., Industry · Terminated
Key facts
| NCT number | NCT00249301 |
|---|---|
| Title | A Study of MLN8054 in Patients With Advanced Solid Tumors |
| Official title | An Open-Label, Dose Escalation Phase 1 Study of MLN8054, a Novel Aurora A Kinase Inhibitor, in Patients With Advanced Solid Tumors |
| Lead sponsor | Millennium Pharmaceuticals, Inc., Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Breast Neoplasm, Colon Neoplasm, Pancreatic Neoplasm, Bladder Neoplasm |
| Intervention type | Drug |
| Interventions | MLN8054 |
| Enrollment | 63 |
| Start date | Oct 1, 2005 |
| Primary completion | Jan 1, 2008 |
| First posted | Nov 7, 2005 |
| Last update posted | Apr 1, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: